GlassScriptPhysician profile
Sharon R Silverman
NPI 1528446499
$975.90
in general payments reported to CMS, 2019-2025
18 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $518 · 2022: $34.27 · 2024: $107 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $151.75 | 2021-2025 | Kisunla, Mounjaro, Zepbound |
| Abbvie INC. | $148.21 | 2021 | |
| Novo Nordisk INC | $128.94 | 2024-2025 | Wegovy, Ozempic |
| Teva Pharmaceuticals USA, INC. | $103.69 | 2021 | |
| Upsher-Smith Laboratories LLC | $60.36 | 2021 | |
| Exact Sciences Corporation | $53.01 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $49.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.36 | 2021 | |
| Boston Scientific Corporation | $42.64 | 2025 | Infinion 16 |
| Paratek Pharmaceuticals, INC. | $36.72 | 2024-2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.43 | 2021 | |
| Millicent US INC | $22.69 | 2025 | Femlyv, Intrarosa |
| Sunovion Pharmaceuticals INC. | $21.77 | 2021 | |
| Astellas Pharma US INC | $20.52 | 2025 | Veozah |
| Adamas Pharmaceuticals, INC. | $16.40 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $15.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.80 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.